Breaking News, Collaborations & Alliances

Isis Earns AstraZeneca Milestone

ISIS-STAT3Rx advances to Phase II trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $7.5 million milestone payment from AstraZeneca for the advancement of ISIS-STAT3Rx (AZD9150) in patients with advanced cancers. Isis will earn the second $7.5 million milestone upon initiation of a Phase II study.  AstraZeneca is currently evaluating ISIS-STAT3Rx in a Phase 1/2 study in patients with advanced metastatic liver cancer.  AstraZeneca plans to initiate additional clinical studies to further evaluate ISIS-STAT3Rx.   In total, Isis is eligible t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters